CRISPR Therapeutics AG
NASDAQ:CRSP 9:43:49 AM EDT
Market Cap (Intraday) | 13.96B |
Current PE | N/A |
Forward PE | N/A |
2yr Forward PE | N/A |
10-Day MA | $189.01 |
50-Day MA | $151.78 |
200-Day MA | $97.42 |
CRISPR Therapeutics AG Stock, NASDAQ:CRSP
BAARERSTRASSE 14, ZUG, SWITZERLAND CH-6300
Switzerland
Phone: 6173154600
Number of Employees: 188
Description
CRISPR Therapeutics AG focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The CRISPR/Cas9 technology allows for changes to genomic DNA. The company has strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases. It operates in Switzerland, the United States, and the United Kingdom. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.